The impact of GINA suggested drugs for the treatment of asthma on health-related quality of life: A GA2LEN review

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 63, Issue 8, 2008, Pages 1015-1030

  Baiardini, I ^a   Braido, F ^a   Brandi, S ^a   Tarantini, F ^a   Bonini, S ^b   Bousquet, P J ^c   Zuberbier, T ^d   Demoly, P ^c   Canonica, G W ^a,e  

^a UNIVERSITY OF GENOA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

Asthma; GINA guidelines; Quality of life

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CHLOROFLUOROCARBON; CICLESONIDE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; FORMOTEROL; HOUSE DUST ALLERGEN; INFLUENZA VACCINE; LEVALBUTEROL; MOMETASONE FUROATE; MONTELUKAST; OMALIZUMAB; PLACEBO; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE ACETONIDE; TULOBUTEROL; ZAFIRLUKAST; ZILEUTON; ANTIASTHMATIC AGENT;

ASTHMA; CLINICAL TRIAL; DRUG COST; HEALTH CARE SYSTEM; HUMAN; IMMUNOTHERAPY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SPIROMETRY; STRUCTURED QUESTIONNAIRE; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 56149093846     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2008.01823.x     Document Type: Review

References (56)

1. Bousquet J, van Cauwenberge PB, Khaltaev N, ARIA Workshop Group, WHO. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108:S1-S334
2. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLB1/WHO workshop report. NIH Publication Number: 02-3659, 2002
3. Schipper H, Clinch J, Olweny CLM. Quality of life studies: definitions and conceptual issues. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven Press, 1990:11-23
4. Baiardini I, Braido F, Brandi S, Canonica GW. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol 2006;97:419-428
5. Tohda Y, Tsuji F, Kubo H, Haraguchi R, Iwanaga T. Usefulness of QVAR for the treatment of bronchial asthma-with and without use of an inhalation device. J Asthma 2006;43:613-618
6. Lazarus SC, Chinchilli WM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ et al. Smoking affects response to inhaler corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007;175:783- 790
7. Van Aalderen WM, Price D, De Baets FM, Price J. Beclometasone dipropio-nate extrafine aerosol versus fluticasone propionate in children with asthma. Respir Med 2007;101:1585-1593
8. Weiss KB, Paramore C, Liljas B, Revicki DA, Luce BR. Patient satisfaction with budesonide turbohaler versus triamcino-lone acetonide administered via pressurized metered-dose inhaler in a managed care setting. J Asthma 2005;42:769-776
9. Berger WE, Milgrom H, Chervinsky P, Noonan M, Weistein SF, Lutsky BN et al. Effects of treatment with mometa-sone forate dry powder inhaler in children with persistent asthma. Ann Allergy Asthma Immunol 2006;97:672-680
10. Karpel JP, Nayak A, Lumry W, Craig TJ, Kerwin W, Fish Je et al. Inahaled mometasone furoate reduces oral pred-nisone usage and improves lung function in severe persistent asthma. Respir Med 2007;101:628-637
11. Lee DK, Currie GP, Bates Ce, Lipworth BJ. Effects of hydrofluoroalkane for mulations of ciclesonide 400 microgram once daily vs fluticasone 250 microgram twice daily on metacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharmacol 2004;58:26-33
12. Lee DK, Fardon TC, Bates CE, Haggart K, McFarlane LC, Lipworth BJ. Airway and systemic effects of hydrofluoroal-kane formulations of high dose ciclesonide and fluticasone in moderate persistent asthma. Chest 2005;127:851-860
13. Boulet LP, Bateman ED, Voves R, Muller T, Wolf S, Engelstatter R. A randomised study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med 2007;101:1677-1686
14. von Berg A, Engelstatter R, Mimic P, eckovic M Sr, Garcia Garcia ML, Latos T et al. Comparison of the efficacy and safety of ciclesonide 160 ug once daily vs. budesonide 400 ug once daily in children with asthma. Pediatr Allergy Immunol 2007;18:391-400
15. Barnes PJ. Clinical outcome of adding long-acting beta-agonists to inhaled corticosteroids. Respir Med 2001; 95(Suppl B):S12-S16
16. Fujimoto K, Komatsu Y, Yasuo M, Urushihata K, Kubo K. Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids. J Asthma 2006;43:501-507
17. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kume H et al. Comparison of the effects of tulobu-terol patch and salmeterol in moderate to severe asthma. Clin Exp Pharmacol Physiol 2006;33:1016-1021
18. Busse W, Levine B, Andriano K, Lavecchia C, Yegen U. Efficacy, tolera-bility, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study. Clin Ther 2004;26:1587-1598
19. La Force C, Prenner BM, Andriano K, Lavecchia C, Yegen Ue. Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihal-er™) in adolescents and adults with persistent asthma. J Asthma 2005; 42:101-106
20. Skoner DP, Greos LS, Kim KT, Roach JM, Parsey M, Baumgartner RA. Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma. Pediatr Pulmonol 2005;40:477-486
21. Bateman DE, Boushey Ha, Bousquet J, Busse WW, Clark TJ, Pauwels RA et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004;170:836-844
22. Schermer TRJ, Albers JMC, Verblackt HWJ, Costongs RJMG, Westers P.Lower inhaled steroids requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD. Family Pract 2007;24:181-188
23. Rowe BH, Wong E, Blitz S, Diner B,Mackey D, Ross S et al. Adding long-acting beta-agonists to inhaled corticosteroids after discharge from the emergency department for acute asthma: a randomised controlled trial. Acad Emerg Med 2007;14:833-840
24. Kuna P, Peters MJ, Manjra AI, Jorup C, Naja IP, Martinez-Jimenez NE et al. Effect of budesonide/formoterol main tenance and reliever therapy on asthma exacerbation. Int J Clin Pract 2007;61:725-736
25. Price DB, Williams AE, Yoxall S.Salmeterol/fluticasone stable-dose treatment compared with formoterol/budes-onide adjustable maintenance dosing: impact on heath-related quality of life. Respir Res 2007;8:46
26. Pohl WR, Vetter N, Zwick H, Hrubos W. Adjustable maintenance dosing with budesonide/formoterol or budesonide: double-blind study. Respir Med 2006; 100:551-560
27. van den Toorn LM, Prins JB, de Jongste JC, Leman K, Mulder PG, Hoogsteden HC et al. Benefit from anti-inflammatory treatment during clinical remission of atopic asthma. Respir Med 2005; 99:779-787
28. Bruggenjurgen B, Selim D, Kardos P, Richter K, Vogelmeier C, Roll S et al. Economic assessment of adjustable maintenance treatment with budeso-nide/formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics 2005;23:723-731
29. Buhl R, Kardos P, Richter K, Meyer-Sabellek W, Brueggenjuergen B, Willich SN. The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing. Curr Med Res Opin 2004;20:1209-1220
30. Vogelmeier C, D'Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26:819-828
31. Price D, Haughney J, Lloyd A, Hutchinson J, Plumb J. An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Curr Med Res Opin 2004;20:1671-1679
32. Fardon T, Haggart K, Lee DKC,Lipworth BJ. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salme-terol and tiotropium in severe persistent asthma. Respir Med 2007;101:1218-1228
33. Zeiger RS, Bird SR, Kaplan MS, Schatz M, Pearlman DS, Orav EJ et al. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 2005;118:649-657
34. Barnes N, Laviolette M, Allen D, Flood-Page P, Hargreave F, Corris P et al. Effects of montelukast compared to double dose budesonide on airway inflammation and asthma control. Respir Med 2007;101:1652-1658
35. Ilowite J, Webb R, Friedman B, Kerwin E, Bird SR, Hustad CM et al. Addition of montelukast or salmeterol to flutica-sone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004;92:641-648
36. Riccioni G, Della Vecchia R, Di Ilio C,D'Orazio N. Effect of the two different leukotriene receptor antagonists, mont-elukast and zafirlukast, on quality of life: a 12-week randomized study. Allergy Asthma Proc 2004;25:445-448
37. American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and monteluk-ast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007;175:235-242
38. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M et al. Efficacy and tolerability of anti-immu-noglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-717
39. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309-316
40. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescent with moderate-to-severe allergic asthma. J Allergy Clin Immunolc 2004;114:265-269
41. Bousquet J. Pro: immunotherapy is clinically indicated in the management of allergic asthma. Am J Respir Crit Care Med 2001;164:2139-2140
42. Passalacqua G, Pasquali M, Ariano R, Lombardi C, Giardini I, Baiardini I et al. Randomized double-blind controlled study with sublingual carbamy-lated allergoid immunotherapy in mild rhinitis due to mites. Allergy 2006;61:849-854
43. Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007;18:47-57
44. Ameal A, Vega-Chicote JM, Fernandez S, Miranda A, Carmona MJ, Rondon MC et al. Double-blind and placebo-controlled study to assess efficacy and safety of modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 2005;60:1178-1183
45. Alexander C, Tarzi M, Larché M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005;60:1269-1274
46. Bueving HJ, Van der Wouden JC, Raat H, Bernsen RMD, De Jonste JC, Van Suijlekom-Smit LWA et al. Influenza vaccination in asthmatic children: effects on quality of life and symptoms. Eur Respir J 2004;24:925-931
47. Dharmage S, Walters EH, Thien F, Bailey M, Raven J, Wharton C et al. Encasement of bedding does not improve asthma in atopic adult asthmatics. Int Arch Allergy Immunol 2006;139:132-138 [Epub 2005 Dec 21]
48. FDA. Draft guidance for industry on patient-reported outcome measures: use in medicinal product development to support labeling claims. Fed Register 2006;71:5862-5863
49. Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. http://www.emea.europa.eu/ pdfs/human/ewp/1393104en.pdf (July25, 2005) (accessed Dec 7, 2006)
50. 2LEN Review. Allergy 2008;63:660-669
51. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16:802-807
52. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK et al.Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys.Lancet 2006;368:733-743
53. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults.Am J Respir Crit Care Med 2000;162:1391-1396
54. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl 5):S147-S334
55. Schunemann HJ, Jaeschke R, Cook D, Bria W, El-Solh A, Ernst A et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006;174:605-614
56. Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926